이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Samsung Bioepis links up with Takeda to make original drugs
- Collected
- 2017.08.21
- Distributed
- 2017.08.21
- Source
- Go Direct
이미지 확대Samsung Bioepis Monday said the two companies will jointly fund and develop multiple novel biological therapies and has already begun working on their first therapeutic candidate TAK-671 to treat severe acute pancreatitis.
“We highly value Samsung Bioepis’ biosimilar development platform and technology,” said Daniel Curran, head of the center for external innovation at Takeda Pharmaceuticals. “We expect to save time and cost by working close together from research and development to commercialization.”
“This is a global recognition of our advanced platform and technology that enabled us to successfully carry out R&D operations of biosimilars over the past five years,” said Ko Han-sung, chief executive of Samsung Bioepis. “This partnership with Takeda Pharmaceuticals is a great opportunity for us to expand our capacity to new drug development.”
Founded in 2012, Samsung Bioepis is a biopharmaceutical unit of Korea’s largest conglomerate Samsung Group. It produces biosimilars, cheaper versions of biotechnology drugs whose patents have expired. The complex makeup of biologics makes creating copycats extremely difficult. Its two main biosimilars are Brenzys, an etanercept biosimilar marketed as Benepali in Europe, and Renflexis, an infliximab biosimilar sold in Europe as Flixabi.
Japan’s Takeda Pharmaceuticals is the largest pharmaceutical firm in Asia whose sales amounted to $16.1 billion last year.
By Shin Chan-ok
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]